Skip to content
The People's CodeSearch
Menu

Changes to the Code

H.R. 6166 · Lowering Drug Costs for American Families Act ·

In committee · step 2 of 5

Sections are cited like “7 U.S.C. § 2012”: 7 of the , 2012.

26 U.S.C. § 9826 Drug Price Negotiation Program and application of maximum fair prices New section

+15 −0Shown
More for 26 U.S.C. § 9826
1 change the bill asks for here, 1 carried out
  1. Carried out:

    Subchapter B of chapter 100 of the Internal Revenue Code of 1986 is amended by adding at the end the following new section:9826. Drug Price Negotiation Program and application of maximum fair prices (a) In general.— In the case of a group health plan that is treated under section 1197 of the Social Security Act as having in effect an agreement with the Secretary of Health and Human Services under the Drug Price Negotiation Program under part E of title XI of such Act, with respect to a price applicability period (as defined in section 1191(b) of such Act) and a selected drug (as defined in section 1192(c) of such Act) with respect to such period for which coverage is provided under such plan— (1) the provisions of such part shall apply, as applicable— (A) if coverage of such selected drug is provided under such plan if the drug is furnished or dispensed at a pharmacy or by a mail order service, to the plan, and to the participants and beneficiaries enrolled under such plan during such period, with respect to such selected drug, in the same manner as such provisions apply to prescription drug plans and MA–PD plans, and to participants and beneficiaries enrolled under such prescription drug plans and MA–PD plans during such period; and (B) if coverage of such selected drug is provided under such plan if the drug is furnished or administered by a hospital, physician, or other provider of services or supplier, to the plan, to the participants and beneficiaries enrolled under such plan, and to hospitals, physicians, and other providers of services and suppliers during such period, with respect to such drug in the same manner as such provisions apply to the Secretary of Health and Human Services, to participants and beneficiaries entitled to benefits under part A of title XVIII or enrolled under part B of such title, and to hospitals, physicians, and other providers and suppliers participating under title XVIII during such period; (2) the plan shall apply any cost-sharing responsibilities under such plan, with respect to such selected drug, by substituting an amount not more than the maximum fair price negotiated under such part E of title XI for such drug in lieu of the drug price upon which the cost-sharing would have otherwise applied, and such cost-sharing responsibilities with respect to such selected drug may not exceed such maximum fair price; and (3) the Secretary shall apply the provisions of such part E to such plan and such participants and beneficiaries so enrolled in such plan. (b) Notification regarding nonparticipation in Drug Price Negotiation Program.— A group health plan shall publicly disclose in a manner and in accordance with a process specified by the Secretary any election made under section 1197 of the Social Security Act by the plan to not participate in the Drug Price Negotiation Program under part E of title XI of such Act with respect to a selected drug (as defined in section 1192(c) of such Act) for which coverage is provided under such plan before the beginning of the plan year for which such election was made..

    The section already has a provision under this letter or number, so it would have two.

The Code already has a 26 U.S.C. § 9826, a different section added since this bill was written, so this would be a second section under that number.

§ 9826(a)–(b)

§ 9826. [inserted: Drug Price Negotiation Program and application of maximum fair prices]

(a) [inserted: In general.—] [inserted: In the case of a group health plan that is treated under section 1197 of the Social Security Act as having in effect an agreement with the Secretary of Health and Human Services under the Drug Price Negotiation Program under part E of title XI of such Act, with respect to a price applicability period (as defined in section 1191(b) of such Act) and a selected drug (as defined in section 1192(c) of such Act) with respect to such period for which coverage is provided under such plan—]

(1) [inserted: the provisions of such part shall apply, as applicable—]

(A) [inserted: if coverage of such selected drug is provided under such plan if the drug is furnished or dispensed at a pharmacy or by a mail order service, to the plan, and to the participants and beneficiaries enrolled under such plan during such period, with respect to such selected drug, in the same manner as such provisions apply to prescription drug plans and MA–PD plans, and to participants and beneficiaries enrolled under such prescription drug plans and MA–PD plans during such period; and]

(B) [inserted: if coverage of such selected drug is provided under such plan if the drug is furnished or administered by a hospital, physician, or other provider of services or supplier, to the plan, to the participants and beneficiaries enrolled under such plan, and to hospitals, physicians, and other providers of services and suppliers during such period, with respect to such drug in the same manner as such provisions apply to the Secretary of Health and Human Services, to participants and beneficiaries entitled to benefits under part A of title XVIII or enrolled under part B of such title, and to hospitals, physicians, and other providers and suppliers participating under title XVIII during such period;]

(2) [inserted: the plan shall apply any cost-sharing responsibilities under such plan, with respect to such selected drug, by substituting an amount not more than the maximum fair price negotiated under such part E of title XI for such drug in lieu of the drug price upon which the cost-sharing would have otherwise applied, and such cost-sharing responsibilities with respect to such selected drug may not exceed such maximum fair price; and]

(3) [inserted: the Secretary shall apply the provisions of such part E to such plan and such participants and beneficiaries so enrolled in such plan.]

(b) [inserted: Notification regarding nonparticipation in Drug Price Negotiation Program.—] [inserted: A group health plan shall publicly disclose in a manner and in accordance with a process specified by the Secretary any election made under section 1197 of the Social Security Act by the plan to not participate in the Drug Price Negotiation Program under part E of title XI of such Act with respect to a selected drug (as defined in section 1192(c) of such Act) for which coverage is provided under such plan before the beginning of the plan year for which such election was made.]

26 U.S.C. § 9827 Comprehensive coverage New section

+46 −0Shown
More for 26 U.S.C. § 9827
1 change the bill asks for here, 1 carried out
  1. Carried out:

    Subchapter B of chapter 100 of the Internal Revenue Code of 1986, as amended by section 101, is further amended by adding at the end the following new section:9827. Comprehensive coverage (a) Cost-Sharing limitation.— (1) In general.— A group health plan shall ensure that— (A) any annual cost-sharing imposed under the plan (including any such cost-sharing so imposed with respect to prescription drugs) does not exceed the dollar amounts specified in paragraph (2); and (B) any annual cost-sharing imposed under the plan with respect to prescription drugs does not exceed the dollar amounts specified in paragraph (3). (2) Limitation on overall out-of-pocket cost-sharing.— For purposes of paragraph (1)(A), the dollar amounts specified in this paragraph are the following: (A) With respect to self-only coverage— (i) for plan years beginning in 2027, the dollar amount in effect under section 1302(c)(1) of the Patient Protection and Affordable Care Act for such coverage for plan years beginning in 2014, increased by an amount equal to the product of that amount and the premium adjustment percentage specified in paragraph (4) of such section for the calendar year; and (ii) for plan years beginning in 2028 or a subsequent year, the dollar amount in effect under this subparagraph for plan years beginning in 2027, increased by an amount equal to the product of that amount the premium adjustment percentage specified in paragraph (4) for the calendar year. (B) With respect to coverage other than self-only coverage, for plan years beginning in 2027 or a subsequent year, twice the amount in effect under subparagraph (A) for such plan year. If the amount of any increase under subparagraph (A) is not a multiple of $50, such increase shall be rounded to the next lowest multiple of $50. (3) Limitation on prescription drug out-of-pocket cost-sharing.— For purposes of paragraph (1)(B), the dollar amounts specified in this paragraph are the following: (A) With respect to self-only coverage— (i) for plan years beginning in 2027, $2,000; and (ii) for plan years beginning in 2028 or a subsequent year, the dollar amount in effect under this subparagraph for plan years beginning in 2027, increased by an amount equal to the product of that amount and the premium adjustment percentage under paragraph (4) for the calendar year. (B) With respect to coverage other than self-only coverage, for plan years beginning in 2027 or a subsequent year, twice the amount in effect under subparagraph (A) for such plan year. If the amount of any increase under subparagraph (A) is not a multiple of $50, such increase shall be rounded to the next lowest multiple of $50. (4) Premium adjustment percentage.— For purposes of paragraphs (2)(A)(ii) and (3)(A)(ii), the premium adjustment percentage for any calendar year is the percentage (if any) by which the average per capita premium for health insurance coverage in the United States for the preceding calendar year (as estimated by the Secretary no later than October 1 of such preceding calendar year) exceeds such average per capita premium for 2026 (as determined by the Secretary). (5) Cost-sharing.— In this section: (A) In general.— The term cost-sharing includes— (i) deductibles, coinsurance, copayments, or similar charges; and (ii) any other expenditure required of an insured individual which is a qualified medical expense (within the meaning of section 223(d)(2) of the Internal Revenue Code of 1986) with respect to essential health benefits covered under the plan. (B) Exceptions.— Such term does not include premiums, balance billing amounts for non-network providers, or spending for non-covered services. (6) Implementation.— The Secretary may implement the provisions of this subsection by subregulatory guidance, interim final rule, or otherwise. (b) Dental only.— This section shall not apply to a plan described in section 1311(d)(2)(B)(ii) of the Patient Protection and Affordable Care Act..

§ 9827(a)–(b)

§ 9827. [inserted: Comprehensive coverage]

(a) [inserted: Cost-Sharing limitation.—]

(1) [inserted: In general.—] [inserted: A group health plan shall ensure that—]

(A) [inserted: any annual cost-sharing imposed under the plan (including any such cost-sharing so imposed with respect to prescription drugs) does not exceed the dollar amounts specified in paragraph (2); and]

(B) [inserted: any annual cost-sharing imposed under the plan with respect to prescription drugs does not exceed the dollar amounts specified in paragraph (3).]

(2) [inserted: Limitation on overall out-of-pocket cost-sharing.—] [inserted: For purposes of paragraph (1)(A), the dollar amounts specified in this paragraph are the following:]

(A) [inserted: With respect to self-only coverage—]

(i) [inserted: for plan years beginning in 2027, the dollar amount in effect under section 1302(c)(1) of the Patient Protection and Affordable Care Act for such coverage for plan years beginning in 2014, increased by an amount equal to the product of that amount and the premium adjustment percentage specified in paragraph (4) of such section for the calendar year; and]

(ii) [inserted: for plan years beginning in 2028 or a subsequent year, the dollar amount in effect under this subparagraph for plan years beginning in 2027, increased by an amount equal to the product of that amount the premium adjustment percentage specified in paragraph (4) for the calendar year.]

(B) [inserted: With respect to coverage other than self-only coverage, for plan years beginning in 2027 or a subsequent year, twice the amount in effect under subparagraph (A) for such plan year.]

[inserted: If the amount of any increase under subparagraph (A) is not a multiple of $50, such increase shall be rounded to the next lowest multiple of $50.]

(3) [inserted: Limitation on prescription drug out-of-pocket cost-sharing.—] [inserted: For purposes of paragraph (1)(B), the dollar amounts specified in this paragraph are the following:]

(A) [inserted: With respect to self-only coverage—]

(i) [inserted: for plan years beginning in 2027, $2,000; and]

(ii) [inserted: for plan years beginning in 2028 or a subsequent year, the dollar amount in effect under this subparagraph for plan years beginning in 2027, increased by an amount equal to the product of that amount and the premium adjustment percentage under paragraph (4) for the calendar year.]

(B) [inserted: With respect to coverage other than self-only coverage, for plan years beginning in 2027 or a subsequent year, twice the amount in effect under subparagraph (A) for such plan year.]

[inserted: If the amount of any increase under subparagraph (A) is not a multiple of $50, such increase shall be rounded to the next lowest multiple of $50.]

(4) [inserted: Premium adjustment percentage.—] [inserted: For purposes of paragraphs (2)(A)(ii) and (3)(A)(ii), the premium adjustment percentage for any calendar year is the percentage (if any) by which the average per capita premium for health insurance coverage in the United States for the preceding calendar year (as estimated by the Secretary no later than October 1 of such preceding calendar year) exceeds such average per capita premium for 2026 (as determined by the Secretary).]

(5) [inserted: Cost-sharing.—] [inserted: In this section:]

(A) [inserted: In general.—] [inserted: The term “cost-sharing” includes—]

(i) [inserted: deductibles, coinsurance, copayments, or similar charges; and]

(ii) [inserted: any other expenditure required of an insured individual which is a qualified medical expense (within the meaning of section 223(d)(2) of the Internal Revenue Code of 1986) with respect to essential health benefits covered under the plan.]

(B) [inserted: Exceptions.—] [inserted: Such term does not include premiums, balance billing amounts for non-network providers, or spending for non-covered services.]

(6) [inserted: Implementation.—] [inserted: The Secretary may implement the provisions of this subsection by subregulatory guidance, interim final rule, or otherwise.]

(b) [inserted: Dental only.—] [inserted: This section shall not apply to a plan described in section 1311(d)(2)(B)(ii) of the Patient Protection and Affordable Care Act.]

26 U.S.C. § 9828 Requirements with respect to cost-sharing for certain insulin products New section

+23 −0Shown
More for 26 U.S.C. § 9828
1 change the bill asks for here, 1 carried out
  1. Carried out:

    Subchapter B of chapter 100 of the Internal Revenue Code of 1986, as amended by sections 101 and 301, is further amended by adding at the end the following new section:9828. Requirements with respect to cost-sharing for certain insulin products (a) In general.— For plan years beginning on or after January 1, 2027, a group health plan shall provide coverage of selected insulin products, and with respect to such products, shall not— (1) apply any deductible; or (2) impose any cost-sharing in excess of the lesser of, per 30-day supply— (A) $35; or (B) the amount equal to 25 percent of the negotiated price of the selected insulin product net of all price concessions received by or on behalf of the plan, including price concessions received by or on behalf of third-party entities providing services to the plan, such as pharmacy benefit management services. (b) Definitions.— In this section: (1) Selected insulin products.— The term selected insulin products means at least one of each dosage form (such as vial, pump, or inhaler dosage forms) of each different type (such as rapid-acting, short-acting, intermediate-acting, long-acting, ultra long-acting, and premixed) of insulin (as defined below), when available, as selected by the group health plan. (2) Insulin defined.— The term insulin means insulin that is licensed under subsection (a) or (k) of section 351 of the Public Health Service Act (42 U.S.C. 262) and continues to be marketed under such section, including any insulin product that has been deemed to be licensed under section 351(a) of such Act pursuant to section 7002(e)(4) of the Biologics Price Competition and Innovation Act of 2009 (Public Law 111–148) and continues to be marketed pursuant to such licensure. (c) Out-of-Network providers.— Nothing in this section requires a plan that has a network of providers to provide benefits for selected insulin products described in this section that are delivered by an out-of-network provider, or precludes a plan that has a network of providers from imposing higher cost-sharing than the levels specified in subsection (a) for selected insulin products described in this section that are delivered by an out-of-network provider. (d) Rule of construction.— Subsection (a) shall not be construed to require coverage of, or prevent a group health plan from imposing cost-sharing other than the levels specified in subsection (a) on, insulin products that are not selected insulin products, to the extent that such coverage is not otherwise required and such cost-sharing is otherwise permitted under Federal and applicable State law. (e) Application of cost-Sharing towards deductibles and out-of-Pocket maximums.— Any cost-sharing payments made pursuant to subsection (a)(2) shall be counted toward any deductible or out-of-pocket maximum that applies under the plan..

§ 9828(a)–(e)

§ 9828. [inserted: Requirements with respect to cost-sharing for certain insulin products]

(a) [inserted: In general.—] [inserted: For plan years beginning on or after January 1, 2027, a group health plan shall provide coverage of selected insulin products, and with respect to such products, shall not—]

(1) [inserted: apply any deductible; or]

(2) [inserted: impose any cost-sharing in excess of the lesser of, per 30-day supply—]

(A) [inserted: $35; or]

(B) [inserted: the amount equal to 25 percent of the negotiated price of the selected insulin product net of all price concessions received by or on behalf of the plan, including price concessions received by or on behalf of third-party entities providing services to the plan, such as pharmacy benefit management services.]

(b) [inserted: Definitions.—] [inserted: In this section:]

(1) [inserted: Selected insulin products.—] [inserted: The term “selected insulin products” means at least one of each dosage form (such as vial, pump, or inhaler dosage forms) of each different type (such as rapid-acting, short-acting, intermediate-acting, long-acting, ultra long-acting, and premixed) of insulin (as defined below), when available, as selected by the group health plan.]

(2) [inserted: Insulin defined.—] [inserted: The term “insulin” means insulin that is licensed under subsection (a) or (k) of section 351 of the Public Health Service Act (42 U.S.C. 262) and continues to be marketed under such section, including any insulin product that has been deemed to be licensed under section 351(a) of such Act pursuant to section 7002(e)(4) of the Biologics Price Competition and Innovation Act of 2009 (Public Law 111–148) and continues to be marketed pursuant to such licensure.]

(c) [inserted: Out-of-Network providers.—] [inserted: Nothing in this section requires a plan that has a network of providers to provide benefits for selected insulin products described in this section that are delivered by an out-of-network provider, or precludes a plan that has a network of providers from imposing higher cost-sharing than the levels specified in subsection (a) for selected insulin products described in this section that are delivered by an out-of-network provider.]

(d) [inserted: Rule of construction.—] [inserted: Subsection (a) shall not be construed to require coverage of, or prevent a group health plan from imposing cost-sharing other than the levels specified in subsection (a) on, insulin products that are not selected insulin products, to the extent that such coverage is not otherwise required and such cost-sharing is otherwise permitted under Federal and applicable State law.]

(e) [inserted: Application of cost-Sharing towards deductibles and out-of-Pocket maximums.—] [inserted: Any cost-sharing payments made pursuant to subsection (a)(2) shall be counted toward any deductible or out-of-pocket maximum that applies under the plan.]

42 U.S.C. § 300gg–6 Comprehensive health insurance coverage

+2 −0Shown
More for 42 U.S.C. § 300gg–6
Read § 300gg–6Only this section
1 change the bill asks for here, 1 carried out
  1. Carried out:

    in section 2707, by adding at the end the following new subsection:(e) Sunset.— The preceding provisions of this section shall not apply with respect to plan years beginning on or after January 1, 2027.; and

§ 300gg–6(c)–(e)

Start of § 300gg–6 to (b) unchanged ·

(c) Child-only plans If a health insurance issuer offers health insurance coverage in any level of coverage specified under section 18022(d) of this title, the issuer shall also offer such coverage in that level as a plan in which the only enrollees are individuals who, as of the beginning of a plan year, have not attained the age of 21.

(d) Dental only This section shall not apply to a plan described in section 18031(d)(2)(B)(ii) 1 of this title.

(e) [inserted: Sunset.—] [inserted: The preceding provisions of this section shall not apply with respect to plan years beginning on or after January 1, 2027.]

42 U.S.C. § 1320f Establishment of program

+2 −2Shown
More for 42 U.S.C. § 1320f
Read § 1320fOnly this section
2 changes the bill asks for here, 2 carried out
  1. Carried out:

    in subparagraph (A), by inserting , or a participant, beneficiary, or enrollee who is enrolled under a group health plan or health insurance coverage offered in the group or individual market (as such terms are defined in section 2791 of the Public Health Service Act) with respect to which there is in effect an agreement with the Secretary under section 1197 with respect to such selected drug as so furnished or dispensed after such selected drug; and

  2. Carried out:

    in subparagraph (B), by inserting , or a participant, beneficiary, or enrollee who is enrolled under a group health plan or health insurance coverage offered in the group or individual market (as such terms are defined in section 2791 of the Public Health Service Act) with respect to which there is in effect an agreement with the Secretary under section 1197 with respect to such selected drug as so furnished or administered after such selected drug.

§ 1320f(c)Other definitions(2)–(4)

Start of § 1320f to (c)(1) unchanged ·

(2) Maximum fair price eligible individual The term “maximum fair price eligible individual” means, with respect to a selected drug—

(A) in the case such drug is dispensed to the individual at a pharmacy, by a mail order service, or by another dispenser, an individual who is enrolled in a prescription drug plan under part D of subchapter XVIII or an MA–PD plan under part C of such subchapter if coverage is provided under such plan for such selected drug[inserted: , or a participant, beneficiary, or enrollee who is enrolled under a group health plan or health insurance coverage offered in the group or individual market (as such terms are defined in section 2791 of the Public Health Service Act) with respect to which there is in effect an agreement with the Secretary under section 1197 with respect to such selected drug as so furnished or dispensed]; and

(B) in the case such drug is furnished or administered to the individual by a hospital, physician, or other provider of services or supplier, an individual who is enrolled under part B of subchapter XVIII, including an individual who is enrolled in an MA plan under part C of such subchapter, if payment may be made under part B for such selected drug[inserted: , or a participant, beneficiary, or enrollee who is enrolled under a group health plan or health insurance coverage offered in the group or individual market (as such terms are defined in section 2791 of the Public Health Service Act) with respect to which there is in effect an agreement with the Secretary under section 1197 with respect to such selected drug as so furnished or administered].

(3) Maximum fair price The term “maximum fair price” means, with respect to a year during a price applicability period and with respect to a selected drug (as defined in section 1320f–1(c) of this title) with respect to such period, the price negotiated pursuant to section 1320f–3 of this title, and updated pursuant to section 1320f–4(b) of this title, as applicable, for such drug and year.

(4) Reference product The term “reference product” has the meaning given such term in section 262(i) of this title.

Rest of § 1320f unchanged ·

42 U.S.C. § 1320f–1 Selection of negotiation-eligible drugs as selected drugs

+1 −1Shown
More for 42 U.S.C. § 1320f–1
Read § 1320f–1Only this section
1 change the bill asks for here, 1 carried out
  1. Carried out:

    Section 1192(a)(4) of the Social Security Act (42 U.S.C. 1320f–1(a)(4)) is amended by striking 20 each place it appears and inserting 50 in each such place.

§ 1320f–1(a)–(b)

Start of § 1320f–1 to (a)(2) unchanged ·

(3) with respect to the initial price applicability year 2028, 15 negotiation-eligible drugs described in subparagraph (A) or (B) of subsection (d)(1) with respect to such year (or, all (if such number is less than 15) such negotiation-eligible drugs with respect to such year); and

(4) with respect to the initial price applicability year 2029 or a subsequent year, [struck: 20][inserted: 50] negotiation-eligible drugs described in subparagraph (A) or (B) of subsection (d)(1), with respect to such year (or, all (if such number is less than [struck: 20][inserted: 50]) such negotiation-eligible drugs with respect to such year).

Subject to subsection (c)(2) and section 1320f–3(f)(5) of this title, each drug published on the list pursuant to the previous sentence and subsection (b)(3) shall be subject to the negotiation process under section 1320f–3 of this title for the negotiation period with respect to such initial price applicability year (and the renegotiation process under such section as applicable for any subsequent year during the applicable price applicability period).

(b) Selection of drugs

(1) In general In carrying out subsection (a), subject to paragraph (2), the Secretary shall, with respect to an initial price applicability year, do the following:

Rest of § 1320f–1 unchanged ·

42 U.S.C. § 1320f–3 Negotiation and renegotiation process

+22 −0Shown
More for 42 U.S.C. § 1320f–3
Read § 1320f–3Only this section
1 change the bill asks for here, 1 carried out
  1. Carried out:

    Section 1194(e) of the Social Security Act (42 U.S.C. 1320f–3(e)) is amended by adding at the end the following new paragraph:(3) Average international market price.— (A) In general.— The average price (which shall be the net average price, if practicable, and volume-weighted, if practicable) for a unit (as defined in subparagraph (C)) of such drug for sales of such drug (calculated across different …

§ 1320f–3(e)–(f)

Start of § 1320f–3 to (e)(2)(C) unchanged ·

(D) The extent to which such drug and therapeutic alternatives to such drug address unmet medical needs for a condition for which treatment or diagnosis is not addressed adequately by available therapy.

In using evidence described in subparagraph (C), the Secretary shall not use evidence from comparative clinical effectiveness research in a manner that treats extending the life of an elderly, disabled, or terminally ill individual as of lower value than extending the life of an individual who is younger, nondisabled, or not terminally ill.

(3) [inserted: Average international market price.—]

(A) [inserted: In general.—] [inserted: The average price (which shall be the net average price, if practicable, and volume-weighted, if practicable) for a unit (as defined in subparagraph (C)) of such drug for sales of such drug (calculated across different dosage forms and strengths of the drug and not based on the specific formulation or package size or package type), as computed (as of the date of publication of such drug as a selected drug under section 1192(a)) in all countries described in clause (ii) of subparagraph (B) that are applicable countries (as described in clause (i) of such subparagraph) with respect to such drug.]

(B) [inserted: Applicable countries.—]

(i) [inserted: In general.—] [inserted: For purposes of subparagraph (A), a country described in clause (ii) is an applicable country described in this clause with respect to a drug if there is available an average price for any unit for the drug for sales of such drug in such country.]

(ii) [inserted: Countries described.—] [inserted: For purposes of this paragraph, the following are countries described in this clause:]

(I) [inserted: Australia.]

(II) [inserted: Canada.]

(III) [inserted: France.]

(IV) [inserted: Germany.]

(V) [inserted: Japan.]

(VI) [inserted: The United Kingdom.]

(C) [inserted: Unit defined.—] [inserted: For purposes of this paragraph, term “unit” means, with respect to a drug, the lowest identifiable quantity (such as a capsule or tablet, milligram of molecules, or grams) of the drug that is dispensed.]

(f) Renegotiation process

(1) In general In the case of a renegotiation-eligible drug (as defined in paragraph (2)) that is selected under paragraph (3), the Secretary shall provide for a process of renegotiation (for years (beginning with 2028) during the price applicability period, with respect to such drug) of the maximum fair price for such drug consistent with paragraph (4).

Rest of § 1320f–3 unchanged ·

42 U.S.C. § 1320f–5 Administrative duties and compliance monitoring

+4 −2Shown
More for 42 U.S.C. § 1320f–5
Read § 1320f–5Only this section
3 changes the bill asks for here, 3 carried out
  1. Carried out:

    in subparagraph (A), by striking and at the end;

  2. Carried out:

    in subparagraph (B), by striking the period and inserting ; and; and

  3. Carried out:

    by adding at the end the following new subparagraph:(C) maximum fair price eligible individuals not described in subparagraph (A) or (B)..

§ 1320f–5(a)Administrative duties(3)–(5)

Start of § 1320f–5 to (a)(2) unchanged ·

(3) The establishment of procedures to carry out the provisions of this part, as applicable, with respect to—

(A) maximum fair price eligible individuals who are enrolled in a prescription drug plan under part D of subchapter XVIII or an MA–PD plan under part C of such subchapter;[struck: and]

(B) maximum fair price eligible individuals who are enrolled under part B of such subchapter, including who are enrolled in an MA plan under part C of such subchapter[struck: .][inserted: ; and]

(C) [inserted: maximum fair price eligible individuals not described in subparagraph (A) or (B).]

(4) The establishment of a negotiation process and renegotiation process in accordance with section 1320f–3 of this title.

(5) The establishment of a process for manufacturers to submit information described in section 1320f–3(b)(2)(A) of this title.

Rest of § 1320f–5 unchanged ·

42 U.S.C. § 1395w–3a Use of average sales price payment methodology

+13 −11Shown
More for 42 U.S.C. § 1395w–3a
Read § 1395w–3aOnly this section
4 changes the bill asks for here, 4 carried out
  1. Carried out:

    in paragraph (1)(A)(i), by striking units and inserting billing units;

  2. Carried out:

    in paragraph (2)(A), by striking for which payment is made under this part and inserting that would be payable under this part if such drug were furnished to an individual enrolled under this part; and

  3. Carried out:

    in subparagraph (A)(i), by striking units and inserting billing units; and

  4. Carried out:

    by striking subparagraph (B) and inserting the following:(B) Total number of billing units.— For purposes of subparagraph (A)(i), the total number of billing units with respect to a part B rebatable drug is determined as follows: (i) Determine the total number of units equal to— (I) the total number of units, as reported under …

§ 1395w–3a(i)Rebate by manufacturers for single source drugs and biologicals with prices increasing faster than inflation(1)–(2)

Start of § 1395w–3a to (i)(1) unchanged ·

(A) Secretarial provision of information Not later than 6 months after the end of each calendar quarter beginning on or after January 1, 2023, the Secretary shall, for each part B rebatable drug, report to each manufacturer of such part B rebatable drug the following for such calendar quarter:

(i) Information on the total number of [inserted: billing ]units of the billing and payment code described in subparagraph (A)(i) of paragraph (3) with respect to such drug and calendar quarter.

(ii) Information on the amount (if any) of the excess average sales price increase described in subparagraph (A)(ii) of such paragraph for such drug and calendar quarter.

(iii) The rebate amount specified under such paragraph for such part B rebatable drug and calendar quarter.

(B) Manufacturer requirement For each calendar quarter beginning on or after January 1, 2023, the manufacturer of a part B rebatable drug shall, for such drug, not later than 30 days after the date of receipt from the Secretary of the information described in subparagraph (A) for such calendar quarter, provide to the Secretary a rebate that is equal to the amount specified in paragraph (3) for such drug for such calendar quarter.

(C) Transition rule for reporting The Secretary may, for each part B rebatable drug, delay the timeframe for reporting the information described in subparagraph (A) for calendar quarters beginning in 2023 and 2024 until not later than September 30, 2025.

(2) Part B rebatable drug defined

(A) In general In this subsection, the term “part B rebatable drug” means a single source drug or biological (as defined in subparagraph (D) of subsection (c)(6)), including a biosimilar biological product (as defined in subparagraph (H) of such subsection) but excluding a qualifying biosimilar biological product (as defined in subsection (b)(8)(B)(iii)), [struck: for][inserted: that] [struck: which][inserted: would] [struck: payment][inserted: be] [struck: is][inserted: payable] [struck: made][inserted: under] [inserted: this part if such drug were furnished to an individual enrolled ]under this part, except such term shall not include such a drug or biological—

(i) if, as determined by the Secretary, the average total allowed charges for such drug or biological under this part for a year per individual that uses such a drug or biological are less than, subject to subparagraph (B), $100; or

(ii) that is a vaccine described in subparagraph (A) or (B) of section 1395x(s)(10) of this title.

§ 1395w–3a(i)(3)Rebate amount(A)–(C)

(i)(2)(B)–(3) unchanged ·

(A) In general For purposes of paragraph (1), the amount specified in this paragraph for a part B rebatable drug assigned to a billing and payment code for a calendar quarter is, subject to subparagraphs (B) and (G) and paragraph (4), the estimated amount equal to the product of—

(i) the total number of [inserted: billing ]units determined under subparagraph (B) for the billing and payment code of such drug; and

(ii) the amount (if any) by which—

(I) the amount equal to—

(aa) in the case of a part B rebatable drug described in paragraph (1)(B) of subsection (b), 106 percent of the amount determined under paragraph (4) of such section2 for such drug during the calendar quarter; or

(bb) in the case of a part B rebatable drug described in paragraph (1)(C) of such subsection, the payment amount under such paragraph for such drug during the calendar quarter; exceeds

(II) the inflation-adjusted payment amount determined under subparagraph (C) for such part B rebatable drug during the calendar quarter.

(B) Total number of [inserted: billing ]units[inserted: .—] For purposes of subparagraph (A)(i), the total number of [struck: units for the ]billing [struck: and][inserted: units] [struck: payment code ]with respect to a part B rebatable drug [struck: furnished during a calendar quarter described in subparagraph (A) ]is [struck: equal][inserted: determined] [struck: to—][inserted: as follows:]

(i) [inserted: Determine the total number of units equal to—]

(I) [inserted: the total number of units, as reported under subsection (c)(1)(B) for each National Drug Code of such drug during the calendar quarter that is two calendar quarters prior to the calendar quarter as described in subparagraph (A), minus]

(II) [inserted: the total number of units with respect to each National Drug Code of such drug for which payment was made under a State plan under title XIX (or waiver of such plan), as reported by States under section 1927(b)(2)(A) for the rebate period that is the same calendar quarter as described in subclause (I).]

[struck: the number of units for the billing and payment code of such drug furnished during such calendar quarter, minus]

(ii) [inserted: Convert the units determined under clause (i) to billing units for the billing and payment code of such drug, using a methodology similar to the methodology used under this section, by dividing the units determined under clause (i) for each National Drug Code of such drug by the billing unit for the billing and payment code of such drug.]

(iii) [inserted: Compute the sum of the billing units for each National Drug Code of such drug in clause (ii).]

[struck: the number of units for such billing and payment code of such drug furnished during such calendar quarter—]

[struck: (I)] [struck: with respect to which the manufacturer provides a discount under the program under section 256b of this title or a rebate under section 1396r–8 of this title; or]

[struck: (II)] [struck: that are packaged into the payment amount for an item or service and are not separately payable.]

(C) Determination of inflation-adjusted payment amount The inflation-adjusted payment amount determined under this subparagraph for a part B rebatable drug for a calendar quarter is—

(i) the payment amount for the billing and payment code for such drug in the payment amount benchmark quarter (as defined in subparagraph (D)); increased by

Rest of § 1395w–3a unchanged ·

42 U.S.C. § 1395w–114b Manufacturer rebate for certain drugs with prices increasing faster than inflation

+10 −102 of 4 shown
More for 42 U.S.C. § 1395w–114b
Read § 1395w–114bOnly this section
4 changes the bill asks for here, 2 carried out
  1. Not carried out:

    in subparagraph (A)(i), by striking the total number of units and all that follows through the semicolon and inserting the following: the total number of units that are used to calculate the average manufacturer price of such dosage form and strength with respect to such part D rebatable drug, as reported by the manufacturer of such drug under section 1927 for each month, with respect to such period;; and

    We can't read how this instruction is worded yet, so it isn't shown in the text.

    Technical detailno-pattern: striking QTEXT and all that follows through the semicolon and inserting the following: QTEXT; and
  2. Carried out:

    by striking subparagraph (B) and inserting the following:(B) Excluded units.— For purposes of subparagraph (A)(i), the Secretary shall exclude from the total number of units for a dosage form and strength with respect to a part D rebatable drug, with respect to an applicable period, the following: (i) Units of each dosage form and …

  3. Not carried out:

    in paragraph (6), by striking information and all that follows through rebatable covered part D drug dispensed and inserting the following: AMP reports.—The Secretary shall provide for a method and process under which, in the case of a manufacturer of a part D rebatable drug that submits revisions to information submitted under section 1927 by the manufacturer with respect to such drug; and

    We can't read how this instruction is worded yet, so it isn't shown in the text.

    Technical detailno-pattern: striking QTEXT and all that follows through QTEXT and inserting the following: QTEXT; and
  4. Carried out:

    by striking subsection (d) and inserting the following:(d) Information.— For purposes of carrying out this section, the Secretary shall use information submitted by manufacturers under section 1927(b)(3) and information submitted by States under section 1927(b)(2)(A)..

§ 1395w–114b(b)(1)In general(A)–(C)

Start of § 1395w–114b to (b)(1)(A)(ii) unchanged ·

(I) the annual manufacturer price (as determined in paragraph (2)) paid for such dosage form and strength with respect to such part D rebatable drug for the period; exceeds

(II) the inflation-adjusted payment amount determined under paragraph (3) for such dosage form and strength with respect to such part D rebatable drug for the period.

(B) Excluded units[inserted: .—] [inserted: For purposes of subparagraph (A)(i), the Secretary shall exclude from the total number of units for a dosage form and strength with respect to a part D rebatable drug, with respect to an applicable period, the following:]

(i) [inserted: Units of each dosage form and strength of such part D rebatable drug for which payment was made under a State plan under title XIX (or waiver of such plan), as reported by States under section 1927(b)(2)(A).]

(ii) [inserted: Units of each dosage form and strength of such part D rebatable drug for which a rebate is paid under section 1847A(i).]

(iii) [inserted: Beginning with plan year 2026, units of each dosage form and strength of such part D rebatable drug for which the manufacturer provides a discount under the program under section 340B of the Public Health Service Act.]

[struck: For purposes of subparagraph (A)(i), beginning with plan year 2026, the Secretary shall exclude from the total number of units for a dosage form and strength with respect to a part D rebatable drug, with respect to an applicable period, units of each dosage form and strength of such part D rebatable drug for which the manufacturer provides a discount under the program under section 256b of this title.]

(C) Reduction or waiver for shortages and severe supply chain disruptions The Secretary shall reduce or waive the amount under subparagraph (A) with respect to a part D rebatable drug and an applicable period—

(i) in the case of a part D rebatable drug that is described as currently in shortage on the shortage list in effect under section 356e of title 21 at any point during the applicable period;

§ 1395w–114b(b)–(f)

(b)(1)(C)(ii)–(5)(C) unchanged ·

(6) Reconciliation in case of revised information The Secretary shall provide for a method and process under which, in the case where a PDP sponsor of a prescription drug plan or an MA organization offering an MA–PD plan submits revisions to the number of units of a rebatable covered part D drug dispensed, the Secretary determines, pursuant to such revisions, adjustments, if any, to the calculation of the amount specified in this subsection for a dosage form and strength with respect to such part D rebatable drug and an applicable period and reconciles any overpayments or underpayments in amounts paid as rebates under this subsection. Any identified underpayment shall be rectified by the manufacturer not later than 30 days after the date of receipt from the Secretary of information on such underpayment.

(c) Rebate deposits Amounts paid as rebates under subsection (b) shall be deposited into the Medicare Prescription Drug Account in the Federal Supplementary Medical Insurance Trust Fund established under section 1395t of this title.

(d) Information[inserted: .—] [inserted: For purposes of carrying out this section, the Secretary shall use information submitted by manufacturers under section 1927(b)(3) and information submitted by States under section 1927(b)(2)(A).]

[struck: For purposes of carrying out this section, the Secretary shall use information submitted by—]

[struck: (1)] [struck: manufacturers under section 1396r–8(b)(3) of this title;]

[struck: (2)] [struck: States under section 1396r–8(b)(2)(A) of this title; and]

[struck: (3)] [struck: PDP sponsors of prescription drug plans and MA organization offering MA–PD plans under this part.]

(e) Civil money penalty If a manufacturer of a part D rebatable drug has failed to comply with the requirement under subsection (a)(2) with respect to such drug for an applicable period, the manufacturer shall be subject to a civil money penalty in an amount equal to 125 percent of the amount specified in subsection (b) for such drug for such period. The provisions of section 1320a–7a of this title (other than subsections (a) (with respect to amounts of penalties or additional assessments) and (b)) shall apply to a civil money penalty under this subsection in the same manner as such provisions apply to a penalty or proceeding under section 1320a–7a(a) of this title.

(f) Limitation on administrative or judicial review There shall be no administrative or judicial review of any of the following:

Rest of § 1395w–114b unchanged ·

42 U.S.C. § 18022 Essential health benefits requirements

+13 −2Shown
More for 42 U.S.C. § 18022
Read § 18022Only this section

42 U.S.C. § 18071 Reduced cost-sharing for individuals enrolling in qualified health plans

+1 −1Shown
More for 42 U.S.C. § 18071
Read § 18071Only this section

26 U.S.C. § 9831 General exceptions

Already in the law
More for 26 U.S.C. § 9831
Read § 9831Only this section

29 U.S.C. § 1191a Special rules relating to group health plans

Couldn't place the change
More for 29 U.S.C. § 1191a
Read § 1191aOnly this section
Step through the changes